cp wire

CP Wire Articles

UCB announced on 4/27/18 that the European Committee for Medicinal Products for Human Use (CHMP) has recommended approval of a label extension for Cimzia (certolizumab pegol), to include a new... read more

Fri, 04/27/18 - 07:10 pm
CP Staff

Eloxx Pharmaceuticals, Inc. (“Eloxx”),  (NASDAQ:ELOX), announced on 4/27/18 that it has received orphan-drug designation from the Food and Drug Administration (FDA) for ELX-02 for treatment of... read more

Fri, 04/27/18 - 03:29 pm
CP Staff

Gilead Sciences, Inc. (NASDAQ:GILD) today announced on 4/27/18 the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has... read more

Fri, 04/27/18 - 09:55 am
CP Staff

Proniras Corporation, an Accelerator Life Science Partners portfolio company, announced on 4/27/18 that it has been awarded a contract potentially worth $89.5 million from the U.S. Department of... read more

Fri, 04/27/18 - 09:45 am
CP Staff
  • Interim futility analysis supports trial coninuation
  • Mirvetuximab soravtansine is the first FRa-targeting ADC

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the... read more

Thu, 04/26/18 - 07:56 pm
CP Staff
  • 9 million women in the US report recurrent yeast infections
  • single dose led to reduced recurrences of vulvovaginal candidiasis
  • will also study against Staphylococcus aureus... read more
Thu, 04/26/18 - 01:44 pm
CP Staff

Innovent Biologics, Inc., announced the completion of its US$150 million Series E round financing.  

This round of financing attracted high quality global institutional investors and... read more

Thu, 04/26/18 - 10:16 am
CP Staff
  • pLADD induced neoantigen-specific CD8+ T cells undetectable before pLADD treatment started
  • pLADD induced an innate response exemplified by gamma delta T cells, also thought to be... read more
Thu, 04/26/18 - 09:55 am
CP Staff

CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, announced that it received an Import Medical Device Market Approval from... read more

Thu, 04/26/18 - 09:12 am
CP Staff

Eloxx Pharmaceuticals, Inc. (Nasdaq:ELOX) on 4/25/18 announced the pricing of an underwritten public offering of 5,130,000 shares of its common stock at a price to the public of $9.75 per share.... read more

Wed, 04/25/18 - 09:51 pm
CP Staff

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, reported on 4/25/18 new positive magnetic resonance efficacy results showing slowed disease progression... read more

Wed, 04/25/18 - 07:39 pm
CP Staff

STEMCELL Technologies  announced on 4/25/18 a $45 million joint funding agreement between the Governments of Canada and British Columbia to help the company build a state-of-the-art advanced... read more

Wed, 04/25/18 - 04:47 pm
CP Staff

Vaxart is a clinical stage biopharmaceutical company that seems to hold a great deal of promise. They are developing several oral tablet vaccines with the most promising being a vaccine for... read more

Wed, 04/25/18 - 01:59 pm
CP Staff
  • AVXS-101, has potential to be first-ever one-time gene replacement therapy for spinal muscular atrophy (SMA), a disease which results in early death or lifelong disability with considerable... read more
Wed, 04/25/18 - 09:46 am
CP Staff

In June of 2017, OrphoMed announced that they had closed a $39 Million series A round to accelerate development of their lead candidate, ORP-101, IBS-D. On 4/25/18 they announced that the FDA has... read more

Wed, 04/25/18 - 09:18 am
CP Staff
  • In SELECT-SUNRISE study, upadacitinib met the primary endpoint of ACR20 (An ACR20 score means that a person's RA has improved by 20%) across all doses (7.5 mg, 15 mg, 30 mg, once-daily) at... read more
Wed, 04/25/18 - 09:07 am
CP Staff

Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), announced on 4/24/18 that new twelve-month data from its PROMISE 1 Phase 3 clinical trial in episodic migraine patients. The data demonstrated that... read more

Tue, 04/24/18 - 11:52 pm
CP Staff

Mirati Therapeutics, Inc. (Nasdaq: MRTX) (the Company or Mirati), On 4/24/18 provided a progress update on its lead development programs and announced updated, positive clinical trial data for... read more

Tue, 04/24/18 - 11:17 pm
CP Staff

Kurt R. Karst provides regulatory counsel to pharmaceutical manufacturers on Hatch-Waxman patent and exclusivity, drug development, pediatric testing, and orphan drugs. He... read more

Tue, 04/24/18 - 07:50 pm
CP Staff

Pfizer received a Complete Response Letter from the FDA on 4/23/18 highlighting the need for additional technical information. Though this is a setback for Pfizer's Herceptin biosimilar program,... read more

Tue, 04/24/18 - 07:43 pm
CP Staff


current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.